Novel SARS-CoV-2 vaccine candidates: Live, recombinant Leishmania

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: David  Sacks
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $18,682
Funding agency: National Institute of Allergy and Infectious Diseases

In order to overexpress SARS CoV-2 spike protein (S) in Leishmania, the full length S gene sequence was amplified by PCR from plasmid pCAGGS containing the Wuhan-Hu-1 spike  and inserted into plasmid pSSU-NEO  using a Gibson Assembly reaction, with the addition of an N-terminal myc tag and a C-terminal HA tag to evaluate spike cleavage into two subunits (S1 and S2) by potential Leishmania proteases. The generated plasmid pSSU-fullS was then linearized with PmeI and PacI enzymes and the purified construct was integrated into Leishmania major Friedlin strain and Leishmania tarentolae TarII strain 18S rRNA locus by transfection (4D-Nucleofector, Lonza). Positive transfectants were selected by geneticin (G418) antibiotic resistance.
Expression of SARS CoV-2 spike was confirmed by Western Blotting using anti-myc and anti-HA antibodies in the three clones tested for each species. Full-length spike protein was detected at expected band size (143 kDa) on blots for all clones of L. major and L. tarentolae transfectants but not in the wild-type (WT) culture samples. 
An L. major clone with the highest expression level of the spike protein (Spike-L. major) was selected  to evaluate mouse immune response to the spike-overexpressing cells. Ten thousand metacyclics purified from WT L. major or Spike-L. major cultures were inoculated intradermally into both C57BL/6J mice ears.   Unexpectedly, the Spike-L. major cells failed to  induce any visible ear lesions while the WT control  produced ulcerated lesions.  At the endpoint of this experiment at 12 wks p.i., fewer than 2,000 Spike-L. major cells were present in the ear, while the resolving lesions in the ears of mice infected with w.t. L. major contained more than 50,000 parasites.   A minimal T cell response against Spike protein was detected in the draining LN of ears infected with Spike-L. major.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><Africa><Antibiotic Resistance><Antibodies><Attenuated><C-terminal><COVID-19 S protein><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><Cell Body><Cell Mediated Immunology><Cell-Mediated Immunity><Cells><Cellular Immunity><CoV-2><CoV2><Disease><Disorder><Dose><Ear><Enzyme Gene><Enzymes><Esteroproteases><Face><G-418><G418><Generations><Genes><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Geneticin><HCV><HIV-1><HIV-I><HIV1><HPV><Hepatitis C virus><Human><Human Immunodeficiency Virus Type 1><Human Papilloma Virus><Human Papillomavirus><Human immunodeficiency virus 1><Immune response><Immunological response><Infectious Human Wart Virus><Leishmania><Leishmania (Leishmania) major><Leishmania major><Leishmania tropica major><Length><Lesion><Lizards><Mice><Mice Mammals><Middle East><Modern Man><Murine><Mus><N-terminal><NH2-terminal><Parasites><Parasitic infection><Peptidases><Peptide Hydrolases><Plasmids><Protease Gene><Proteases><Protein Subunits><Proteinases><Proteins><Proteolytic Enzymes><Reaction><Recombinant DNA Technology><Recombinant Vaccines><Recombinants><Resistance to antibiotics><Resistant to antibiotics><Ribosomal RNA><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><System><T cell response><Testing><Transfection><Vaccines><Western Blotting><Western Immunoblotting><Wuhan coronavirus><antibiotic G 418><antibiotic drug resistance><antibiotic resistant><arm><corona virus disease 2019 vaccine><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><experiment><experimental research><experimental study><faces><facial><genetically engineered><hCoV19><host response><immune system response><immunoresponse><mouse model><murine model><nCoV2><novel><overexpress><overexpression><parasite infection><pre-clinical development><preclinical development><protein blotting><rRNA><tool><vaccination strategy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><viral gene delivery><wart virus>